EU/3/18/2063: Orphan designation for the treatment in solid organ transplantation
CD34+ haematopoietic stem and progenitor cells with CD3+ T-cells
Table of contents
Overview
On 24 August 2018, orphan designation (EU/3/18/2063) was granted by the European Commission to IQVIA RDS Ireland Limited, Ireland, for CD34+ haematopoietic stem and progenitor cells with CD3+ T-cells for treatment in solid organ transplantation.
The sponsorship was transferred to IQVIA RDS Spain S.L. in November 2021.
Key facts
Active substance |
CD34+ haematopoietic stem and progenitor cells with CD3+ T-cells
|
Intended use |
Treatment in solid organ transplantation
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/18/2063
|
Date of designation |
24/08/2018
|
Sponsor |
IQVIA RDS Spain S.L. |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: